本帖最后由 老马 于 2012-1-13 21:20 编辑 $ ~- P1 X8 [/ _2 u$ U- d7 U$ e$ E7 H
/ ?7 h! r7 H2 F爱必妥和阿瓦斯丁的比较4 E4 w- j1 k" O5 M0 a& K4 s; h9 c6 I
7 g U0 V9 c- \" i( b0 ]http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
' K2 n6 n1 R w9 R3 J
; W* O) @, O C f6 v3 J6 m
0 J+ r) @( D( U5 r6 A: p; a& j
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. e n" D+ E& A: i) j==================================================1 U$ x. y0 o" I# K: r. F4 y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): {0 z* w, C: @6 \$ l$ l
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 Q+ L0 Q' J9 V+ K3 A+ dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 ?2 ^8 P0 J: \; c! K( M" g
|